UA97628C2 - Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе - Google Patents

Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе

Info

Publication number
UA97628C2
UA97628C2 UAA200803277A UAA200803277A UA97628C2 UA 97628 C2 UA97628 C2 UA 97628C2 UA A200803277 A UAA200803277 A UA A200803277A UA A200803277 A UAA200803277 A UA A200803277A UA 97628 C2 UA97628 C2 UA 97628C2
Authority
UA
Ukraine
Prior art keywords
immunoglobulin
fragment
region
initial methionine
production
Prior art date
Application number
UAA200803277A
Other languages
English (en)
Ukrainian (uk)
Inventor
Сунг Юб ДЗУНГ
Дзин Сун КИМ
Дзин Хван ШИН
Се-Чанг КВОН
Гван-Сун ЛИ
Дае Хае СОНГ
Original Assignee
Ханми Холдингз Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ханми Холдингз Ко., Лтд. filed Critical Ханми Холдингз Ко., Лтд.
Publication of UA97628C2 publication Critical patent/UA97628C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Abstract

Изобретение относится к способу получения Fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе путем получения экспрессирующего вектора, включающего нуклеотидную последовательность, кодирующую рекомбинантный Fc-фрагмент иммуноглобулина, состоящего из Fc-фрагмента иммуноглобулина, связанного своим концом с шарнирной областью иммуноглобулина с помощью пептидной связи трансформирования прокариотической клетки рекомбинантным экспрессирующим вектором с получением трансформанта; культивирование трансформанта для того, чтобы экспрессировать фрагмент Fc иммуноглобулина в качестве «те
UAA200803277A 2005-08-16 2006-08-16 Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе UA97628C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20050074989 2005-08-16
PCT/KR2006/003207 WO2007021129A1 (en) 2005-08-16 2006-08-16 A method for the mass production of immunoglobulin fc region deleted initial methionine residues

Publications (1)

Publication Number Publication Date
UA97628C2 true UA97628C2 (ru) 2012-03-12

Family

ID=37757762

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803277A UA97628C2 (ru) 2005-08-16 2006-08-16 Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе

Country Status (14)

Country Link
US (1) US7968316B2 (ru)
EP (1) EP1928910B1 (ru)
JP (2) JP5846712B2 (ru)
CN (1) CN101258164B (ru)
AU (1) AU2006280587B2 (ru)
CA (1) CA2619771C (ru)
DK (1) DK1928910T3 (ru)
ES (1) ES2456672T3 (ru)
HK (1) HK1121768A1 (ru)
MY (1) MY149128A (ru)
PT (1) PT1928910E (ru)
RU (1) RU2428430C2 (ru)
UA (1) UA97628C2 (ru)
WO (1) WO2007021129A1 (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680237B2 (en) 2007-06-01 2014-03-25 Gliknik Inc. Immunoglobulin constant region FC receptor binding agents
RU2483081C2 (ru) * 2008-07-23 2013-05-27 Ханми Сайенс Ко.,Лтд.,Kr Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
MX347343B (es) 2010-07-28 2017-04-21 Gliknik Inc Proteinas de fusion de fragmentos de proteinas humanas naturales para crear composiciones de fc de inmunoglobulinas multimerizadas ordenadamente.
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
ES2728169T3 (es) 2012-03-12 2019-10-22 Hanmi Science Co Ltd Procedimiento de cultivo de células de E. coli para alta densidad
KR102073748B1 (ko) * 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
KR101895634B1 (ko) * 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
WO2017052329A1 (en) 2015-09-24 2017-03-30 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
KR20170037247A (ko) * 2015-09-25 2017-04-04 한미약품 주식회사 개시 메티오닌 잔기를 포함하는 면역글로불린 Fc 영역의 생산방법
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
JP2019536823A (ja) 2016-12-05 2019-12-19 ハンミ ファーマシューティカル カンパニー リミテッド 免疫反応が弱化された結合体
CA3043251A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
TW201835098A (zh) 2016-12-09 2018-10-01 美商吉林尼克公司 製備最佳化之多聚化斯塔都聚體(stradomer) gl-2045
CN110305874A (zh) * 2019-06-19 2019-10-08 浙江省肿瘤医院 长爪沙鼠免疫球蛋白IgG1、IgG2重组蛋白、基因及其应用
KR102334315B1 (ko) * 2019-07-18 2021-12-06 한미약품 주식회사 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
KR20210144606A (ko) 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤 유도체의 지속형 결합체의 액상 제제
JP2023526552A (ja) 2020-05-22 2023-06-21 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ三重活性体の持続型結合体の液状製剤
BR112023000515A2 (pt) 2020-07-15 2023-03-21 Hanmi Pharm Ind Co Ltd Composição farmacêutica e seu uso
EP4183419A1 (en) 2020-07-17 2023-05-24 Hanmi Pharm. Co., Ltd. Therapeutic use of combination containing triple agonistic long-acting conjugate or triple agonist
BR112023019917A2 (pt) 2021-04-09 2023-11-14 Hanmi Pharm Ind Co Ltd Uso de uma composição farmacêutica

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
JPS63290899A (ja) * 1987-05-22 1988-11-28 Takeda Chem Ind Ltd ヒトＩｇＥＦｃ蛋白質のフラグメントおよびその製造法
JP2844870B2 (ja) * 1989-07-21 1999-01-13 味の素株式会社 組み替えｄｎａ法によるポリペプチドの製造法
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JP2845558B2 (ja) * 1990-03-30 1999-01-13 ダイセル化学工業株式会社 メチオニンアミノペプチダーゼのｄｎａ配列
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
DE59109032D1 (de) 1990-06-28 1998-09-03 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
JP3512237B2 (ja) * 1994-07-05 2004-03-29 タカラバイオ株式会社 耐熱性メチオニンアミノペプチダーゼ及びその遺伝子
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6315824B1 (en) * 1996-02-02 2001-11-13 Rodrigue V. Lauzon Coacervate stabilizer system
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
AU8182298A (en) 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PL352332A1 (en) 1999-05-19 2003-08-11 Lexigen Pharm Corp Expression and export of interferon-alpha proteins as fc fusion proteins
AU782496B2 (en) 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US20030144187A1 (en) * 1999-09-03 2003-07-31 Colin R. Dunstan Opg fusion protein compositions and methods
US6979556B2 (en) 2000-12-14 2005-12-27 Genentech, Inc. Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
KR20040092783A (ko) 2003-04-29 2004-11-04 매그나칩 반도체 유한회사 비터비 알고리즘을 이용한 트렐리스 디코더와 그의스테이트 그룹핑방법
KR20050047030A (ko) * 2003-11-13 2005-05-19 한미약품 주식회사 약물의 캐리어로서 유용한 ＩｇＧ Ｆｃ 단편 및 그의제조방법
MXPA06006747A (es) * 2003-12-19 2006-08-18 Novo Nordisk As Procesamiento de peptidos y proteinas.

Also Published As

Publication number Publication date
JP2014110816A (ja) 2014-06-19
ES2456672T3 (es) 2014-04-23
EP1928910A1 (en) 2008-06-11
JP5846712B2 (ja) 2016-01-20
JP2009513110A (ja) 2009-04-02
CN101258164A (zh) 2008-09-03
CA2619771C (en) 2012-05-22
US20080293106A1 (en) 2008-11-27
CA2619771A1 (en) 2007-02-22
MY149128A (en) 2013-07-15
BRPI0614516A2 (pt) 2011-03-29
EP1928910A4 (en) 2010-03-24
HK1121768A1 (en) 2009-04-30
CN101258164B (zh) 2013-05-01
EP1928910B1 (en) 2014-01-15
AU2006280587B2 (en) 2011-02-24
DK1928910T3 (en) 2014-03-10
US7968316B2 (en) 2011-06-28
AU2006280587A1 (en) 2007-02-22
RU2428430C2 (ru) 2011-09-10
RU2008110050A (ru) 2009-09-27
WO2007021129A1 (en) 2007-02-22
PT1928910E (pt) 2014-03-06

Similar Documents

Publication Publication Date Title
UA97628C2 (ru) Способ получения fc-фрагмента иммуноглобулина, свободного от начального метионинового остатка, в массовом масштабе
TW200732472A (en) Method for the recombinant expression of a polypeptide
WO2006017325A3 (en) Aav vector compositions and methods for enhanced expression of immunoglobulins the same
IL184112A0 (en) A method for producing polypeptides or proteins in a disulfide-bridged two-chain form
RU2012106148A (ru) Вариантные формы уратоксидазы и их применение
JP2004532033A5 (ru)
WO2007126798A3 (en) Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2004113493A3 (en) Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
MX2009012326A (es) Peptidos de señalizacion.
WO2006073976A3 (en) Compositions, methods, and kits for enhancing protein expression, solubility and isolation
ATE408016T1 (de) Verfahren zur herstellung und sekretion modifizierter peptide
PE20020857A1 (es) Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras
RU2012121884A (ru) Варианты вируса гепатита с
DE69827262D1 (de) Penaeidine: antimikrobielle peptide aus krebstieren
GB0608368D0 (en) Process for making Oligopeptides
ATE466874T1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
WO2007058267A8 (ja) 新規タンパク質及びそれをコードする遺伝子
MXPA05012336A (es) Procedimiento para producir una proteina dirigida a un plastidio en celulas vegetales.
WO2007100358A3 (en) Convergent synthesis of proteins by kinetically controlled ligation
WO2006029343A3 (en) Peptides that selectively home to heart vasculature and related conjugates and methods
WO2003106971A3 (en) VARIANTS OF DOLLAR G (B) CYSTATHIONIN HUMAN SYNTHASE AND PROCESSES FOR THEIR PRODUCTION
TW200505943A (en) Polypeptide
IL162133A0 (en) Method of increasing protein expression, proteins and polynucleotides
WO2009032181A3 (en) Methods and intermediates for chemical synthesis of polypeptides and proteins